[Comment] Non-invasive tests in MASH: clinical practice versus trials

Non-invasive tests (NITs) are central to clinical decision making in metabolic dysfunction-associated steatotic liver disease, including risk stratification, treatment decisions, referral pathways, and recruitment into clinical trials.1 As pharmacological treatments for metabolic dysfunction-associated steatohepatitis (MASH) become more widely available, the importance of accurately identifying fibrosis stage has grown considerably. In clinical drug trials on MASH, the objective is usually to id